How to Start a GLP-1 Weight Loss Telehealth Brand in 2026

Checked October 18, 2026. Prices are entry prices from the Telehealth Match database (our sister comparison site) unless noted.

The medications

GLP-1s aren't controlled substances. Phentermine is Schedule IV (21 CFR 1308.14). If you add it, the DEA's December 31, 2026 telemedicine deadline applies (our structure guide).

Visits and labs

Because the drugs aren't controlled, async intake is common, but state rules on questionnaire-only prescribing still apply. The labels set the clinical screen: a boxed warning for thyroid C-cell tumors, contraindication with a personal or family history of medullary thyroid cancer or MEN 2, and warnings including pancreatitis, gallbladder disease and low blood sugar with certain diabetes drugs. Eligibility follows the labels: obesity, or overweight with a weight-related condition. Brands typically verify ID and weight or BMI, and many add a metabolic lab panel. If labs or consults are mandatory, include them in the advertised price (see the FTC section below).

What brands charge

Branded injectable offers split into two groups. One quotes $199–$600, which is the manufacturer's self-pay price plus a membership. The other quotes $650–$1,498, the list price filled at the patient's own pharmacy.

Manufacturer self-pay prices set the floor. NovoCare lists the Wegovy pill at $149 (1.5 mg), $199 (4 mg) and $299 (9 and 25 mg) a month, and Wegovy pens at $349 after a $199 introductory price (NovoCare). TrumpRx lists Wegovy pill at $149, Wegovy pen at $199 and Zepbound at $299 (TrumpRx). For branded drugs, your margin is the membership and care you add on top.

Retention

GLP-1 patients stop fast. In 125,474 adults, 64.8% of patients without type 2 diabetes stopped within a year and 72% overall within two years, though about a third restarted (JAMA Network Open, 2025). Larger weight loss went with less stopping. Build for this:

• A maintenance plan after the main weight-loss phase (lower doses, nutrition and strength coaching).
• Restart flows for patients who pause.
• Adjacent products such as labs, menopause care or skin for women, and hair for men (verticals compared).
• Acquisition that pays back within months, not a year. Model it in the profit calculator.

The rules that decide whether you survive

• No "same active ingredient as Wegovy." FDA has cited this, along with "generic," "FDA-approved" and branding that implies you're the compounder, in letters to Hims, MEDVi and dozens of others (503A vs 503B, MEDVi teardown).
• Show the real price. The FTC's NextMed order involved advertised prices that left out the drug, labs and consult, plus fake reviews and a hard cancellation (FTC).
• Make subscriptions honest. The FTC's July 2026 suit against Hims alleges charging before a provider consult, unclear refills and a buried cancel flow (FTC). Put price and refill terms before payment, get clear consent to recurring billing, and make cancelling easy.
• Keep ad pixels off intake pages. The same case alleges health data was shared with ad platforms.
• Ads need LegitScript. Meta's weight-loss ads must target adults 18+ and avoid outcome promises without disclaimers. Prescription weight-loss ads need LegitScript plus Meta authorization (Meta, our LegitScript guide).

Launch checklist

1. Choose your clinician network and pharmacy (partners compared). Confirm they support branded self-pay programs as well as compounded options.
2. Lead with FDA-approved drugs. Offer compounded options only where your clinicians document a real patient-specific need.
3. Price a membership that covers care, coaching and support, and show the total cost up front.
4. Build maintenance and restart programs from day one.
5. Write claims to FDA and FTC rules, and get LegitScript before paid ads.
6. Check costs in the launch cost estimator.

---